Trade TGTX stock anytime, 24x5 in Singapore
Regulated by
Monetary Authority of Singapore (MAS)
Trusted by
400,000+ users
TG Therapeutics, Inc. (TGTX) is trading at US$64.56, down 1.82% today as of Nov 12, 16:00 EST. The company has a market capitalisation of US$9.79B. Over the past 52 weeks, TGTX has traded between US$26.76 and US$68.03. On Syfe you can trade TGTX with $0 commission and add it to your watchlist.
| Previous close | US$65.76 |
|---|---|
| Market cap | US$9.79B |
| P/E ratio | 25.38 |
| 52-week range | US$26.76 – US$68.03 |
| Volume | 1.58M |
| Exchange | US |
TG Therapeutics, Inc.
TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.
Year: 1995
TG Therapeutics Q2 Earnings Fall, Revenue Rises; Fiscal 2026 Revenue Outlook Raised
Aug 3, 11:23 AM · MT Newswires
--Earnings Flash (TGTX) TG Therapeutics Posts Q2 EPS $0.05, vs. FactSet Est of $0.31
Aug 3, 11:04 AM · MT Newswires
TG Therapeutics, Inc. (TGTX) stock is trading at US$64.56, -1.82% from the previous close of US$65.76.
The market cap for TG Therapeutics, Inc. (TGTX) stock is approximately US$9.79B.
The price-to-earnings ratio for TG Therapeutics, Inc. (TGTX) is 25.38, based on the latest reported earnings.
The 52-week high for TG Therapeutics, Inc. (TGTX) stock is US$68.03.
The 52-week low for TG Therapeutics, Inc. (TGTX) stock is US$26.76.
TG Therapeutics, Inc. (TGTX) does not currently pay a dividend.
Stay on top of TGTX
Price moves, news and earnings — straight to your inbox.
Snapshot
Popular Stocks in Singapore
